Is Low-Dose-Rate Endorectal Brachytherapy a New Treatment Method for Locally Advanced Distal Rectal Cancer? by 諛깆듅�쁺
pISSN 2287-9714   eISSN 2287-9722
www.coloproctol.org
Annals of
Coloproctology
www.coloproctol.org 115
Is Low-Dose-Rate Endorectal Brachytherapy a New 
Treatment Method for Locally Advanced Distal Rectal 
Cancer?
Seung Hyuk Baik
Division of Colon and Rectal Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
Editorial
Ann Coloproctol 2015;31(4):115-116
http://dx.doi.org/10.3393/ac.2015.31.4.115
In the treatment of locally advanced rectal cancer, preoperative 
chemoradiotherapy improved the rate of local recurrence after 
surgery and anal sphincter preservation [1]. Because it resulted in 
down-staging of tumors and changes of histologic characteristics, 
it is now regarded as the standard treatment in the patients with 
stages II-III advanced rectal cancer [2]. Conventional preopera-
tive chemoradiotherapy used a dose of 50.4 Gy with concurrent 
chemotherapy before surgery. However, there were concerns be-
cause of increased risks of radiation toxicity and morbidity after 
external beam irradiation. 
In these regards, the endocavitary brachytherapy technique was 
introduced to reduce radiation-related toxicity and to down-stage 
the primary resectable rectal cancer [3]. Endorectal brachytherapy 
has advantages because it can deliver a high dose of radiation 
around the tumor target and spare normal tissues such as small 
bowel, urinary bladder and skin. Vuong et al. [4] reported that a 
high dose rate of endorectal brachytherapy as preoperative 
chemoradiotherapy can reduce local recurrence with favorable 
toxicity compared with external mean radiotherapy. 
This article reported the phase-II clinical outcomes of low-dose-
rate endorectal brachytherapy as a boost to neoadjuvant chemo-
radiotherapy compared with conventional preoperative chemora-
diotherapy for the treatment of locally advanced rectal cancer [5]. 
It was demonstrated that endorectal brachytherapy showed a 
more decreased rate of pathologic tumor size and tumor stage. In 
addition, there was a higher rate of pathologic complete response 
and acceptable toxicity after endorectal brachytherapy compared 
with concurrent neoadjuvant chemoradiatherapy only. Although 
this study evaluated only 34 patients as a phase-II clinical trial, the 
results are meaningful to suggest the efficacy and safety of low-
dose rate endorectal brachytherapy for the treatment of locally 
advanced distal rectal cancer. However, according to a recent re-
port for the long-term results of a randomized trial for brachy-
therapy for locally advanced rectal cancer, there were no benefits 
of 5-year overall survival and progression-free survival after 
brachytherapy in spite of increased pathologic tumor regression 
[6]. The results of this study might decrease justification of the use 
of brachytherapy for locally advanced rectal cancer in terms of 
oncologic outcomes. Moreover, brachytherapy is a complicated 
treatment procedure compared to conventional preoperative 
chemoradiotherapy. Without a doubt, the present study needs a 
further large-scale randomized phase III study to assure oncologic 
benefits compared to conventional chemoradiotherapy or high-
dose-rate endorectal brachytherapy as a boost to conventional 
neoadjuvant chemoradiotherapy. However, in terms of dose re-
duction of brachytherapy in this study, I am looking forward to 
seeing not only oncologic outcomes but also better short-term 
clinical outcomes in the future investigation of the present study.
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